Category: Latest News
-
Gold Prices Hover Near $3,400/oz as Markets Eye September Fed Move; Economic Data Awaited
Gold remained close to a two-week high in Asian trade Thursday, supported by rising expectations that the Federal Reserve could cut interest rates in September amid ongoing tensions between President Donald Trump and the central bank. Spot gold approached $3,400 per ounce this week but stalled just below that threshold as the U.S. dollar strengthened…
-
Oil Slides as India Tariffs and U.S. Inventory Reports Stir Caution
Oil prices softened in Asian trading Thursday as investors weighed a larger-than-expected drop in U.S. crude inventories against the effect of new U.S. tariffs on Indian oil imports. By 21:34 ET (01:34 GMT), October Brent futures were down 0.5% at $67.71 per barrel, while WTI futures fell 0.6% to $63.80 per barrel. U.S. Crude Draw…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, Markets React to Nvidia Earnings, Tesla Sales Decline, and Japan Trade News
U.S. stock futures showed mixed activity Thursday, with Nvidia’s earnings pressuring technology stocks. At the same time, Tesla’s European sales fell sharply in July, and uncertainty over the U.S.-Japan trade deal emerged after Tokyo’s chief negotiator canceled a planned visit to Washington. Nvidia Slips on China Concerns Despite Strong Earnings Nvidia (NASDAQ:NVDA) reported impressive quarterly…
-
Nvidia tops Q2 expectations, but China restrictions weigh on data center revenue
Nvidia delivered stronger-than-expected second-quarter results on Wednesday, though revenue from its data center business came in just shy of forecasts as U.S. limits on H20 chip exports to China took a toll. Shares of NVIDIA Corporation (NASDAQ:NVDA) slipped roughly 2% in after-hours trading following the release. For the quarter ending July 31, the chipmaker posted…
-
S&P 500 Edges Up To Record Closing High Ahead Of Nvidia Earnings
After ending yesterday’s choppy trading session mostly higher, stocks saw some further upside during trading on Wednesday. While buying interest was somewhat subdued, the S&P 500 managed to reach a new record closing high. The major averages all posted modest gains on the day. The Dow rose 147.16 points or 0.3 percent to 45,565.23, the…
-
Krispy Kreme shares downgraded to sell by JPMorgan amid turnaround execution risks
JPMorgan lowered its rating on Krispy Kreme (NASDAQ:DNUT) to Underweight from Neutral, citing uncertainty around the company’s turnaround plan and weakening U.S. business trends. In a note, the analysts said they continue “to not publish a price target,” emphasizing that the stock has dropped from its July 2021 IPO price of $17 to roughly $3.73…
-
Rexford Industrial Realty shares surge after Elliott stake disclosure
Rexford Industrial Realty (NYSE:REXR) shares climbed more than 5% on Wednesday following a Bloomberg report indicating that activist investor Elliott Investment Management has acquired a significant stake in the Los Angeles-based real estate investment trust. Sources familiar with the situation said that Elliott’s holding positions it among Rexford’s top five shareholders, although the hedge fund’s…
-
Greenwave shares dip after receiving another Nasdaq delinquency notice
Greenwave Technology Solutions Inc (NASDAQ:GWAV) stock fell 2.3% in Wednesday premarket trading after the metal recycling firm received an additional delinquency notice from Nasdaq for not submitting required financial reports on time. The company disclosed that it received this notice on August 22, 2025, regarding its delay in filing the Quarterly Report on Form 10-Q…
-
Azitra shares surge after first patient receives ATR04-484 in Phase 1/2 trial
Azitra Inc (AMEX:AZTR) stock jumped 67% in premarket trading Wednesday following the announcement that the first patient has been dosed in the Phase 1/2 trial for ATR04-484, a potential treatment for EGFR inhibitor-associated rash. The candidate, a topical live biotherapeutic, aims to treat a condition affecting roughly 150,000 people annually in the U.S. It has…
-
BeOne Medicines shares dip after EU greenlights TEVIMBRA for lung cancer
BeOne Medicines AG (NASDAQ:ONC) stock fell 3.2% following the European Commission’s approval of TEVIMBRA (tislelizumab) for treating resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The approval stems from the Phase 3 RATIONALE-315 trial, which showed that TEVIMBRA combined with platinum-based chemotherapy before surgery, followed by TEVIMBRA monotherapy, provided a statistically significant…